Weiji Shi, MS

Research Biostatistician
Office Phone:
646-735-8123
Office Fax:
646-735-0010
E-mail:
shiw@mskcc.org

Current Research

Ms. Shi's main collaboration has been with the Gastrointestinal Oncology Service, Gastric and Mixed Tumor Service, and currently with members from various services. She has been involved in many projects including 1) assessment of treatment effects on outcomes for various cancer populations, and in vitro and in vivo animal studies, 2) developing prognostic models on outcomes for a variety of cancer patients, 3) assessment of molecular and genetic markers in predicting outcomes for many cancer populations, 4) evaluation of health related quality of life and cognitive functions following treatments, 5) estimation of cumulative incidence rate of secondary or primary malignancies and standardized incidence/mortality ratio for cancer populations, individuals with Bloom's Syndrome and colorectal adenomas, 6) comparisons of accuracy of diagnostic imaging techniques and mortality probability models for cancer patients, and 7) assisting in statistical design for clinical trials and a randomized, placebo-controlled intervention trial to prevent gastric cancer.

Ms. Shi's current research interests lie in 1) developing prognostic models, 2) missing data structure and imputation, and 3) analysis of longitudinal data. Her main focus is on multi-dimensional exploration of data, dimension reduction techniques, data transformation and imputation, categorization of prognostic factor in univariable and/or multivariable settings, verification of model fitting, and multiple testing adjustments.

Publications by Weiji Shi

Selected Publications

  1. Zelefsky M, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. International journal of radiation oncology, biology, physics 2009; 75(5):1350-6.
  2. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Journal of Clinical Oncology 2009; 27(25):4062-4067.
  3. Fontes ML, Amar D, Kulak A, Koval K, Zhang H, Shi W, Thaler H. Increased preoperative white blood cell count predicts postoperative atrial fibrillation after coronary artery bypass surgery. Journal of Cardiothoracic and Vascular Anesthesia 2009; 23 (4):484-487.
  4. Garg K, Leitao MM Jr, Wynveen CA, Sica GL, Shia J, Shi W, Soslow RA. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Modern Pathology 2009 Oct 23 [Epub ahead of print].
  5. Amar D, Munoz D, Shi W, Zhang H, Thaler HT. A clinical prediction rule for pulmonary complications after thoracic surgery for primary lung cancer. Anesthesia & Analgesia 2009 Oct 27 [Epub ahead of print].